Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181739 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| Iodomethane SCHEMBL27623269 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| SCHEMBL33267 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| SCHEMBL29875298 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| SCHEMBL17836733 | 0.81 | DYRK1A (0.53) | ALDH1A1NPC1RAB9AMAPTGAA | |
| SCHEMBL92781 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| SCHEMBL25873114 | 0.79 | POLB (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| SCHEMBL2174373 | 0.78 | RAB9A (0.50) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| Bromide SCHEMBL10996884 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10 | |
| SCHEMBL2749682 | 0.76 | DYRK1A (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240318052-A1 | METHOD OF UNDERWATER BONDING | HENKEL AG & CO KGAA (DE) | 2024-09-26 | — | — | US | claimed |
| CN-118355041-A | Method for underwater bonding | 汉高股份有限及两合公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2023099777-A1 | METHOD OF UNDERWATER BONDING | Henkel IP & Holding GmbH (DE) | 2023-06-08 | — | — | WO | claimed |
| CN-113045563-A | Preparation method of blue light spectrum sensitizing agent | 上海泓博智源医药股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| EP-3464446-B1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2021-06-23 | — | — | EP | claimed |
| CN-109476874-B | Two-part cyanoacrylate curable adhesive systems | 汉高知识产权控股有限责任公司 | 2021-04-16 | — | — | CN | claimed |
| US-10655015-B2 | Tire crumb-based bitumen polymer for producing a lower viscosity asphalt with improved tolerance to high temperatures | Argopro Group LLC (US) | 2020-05-19 | — | — | US | claimed |
| CN-111116573-A | Near-infrared fluorescent probe for simultaneously detecting DNA and RNA under dual channels and preparation method and application thereof | 中山大学 | 2020-05-08 | — | — | CN | claimed |
| US-20200095424-A1 | TIRE CRUMB-BASED BITUMEN POLYMER FOR PRODUCING A LOWER VISCOSITY ASPHALT WITH IMPROVED TOLERANCE TO HIGH TEMPERATURES | Argopro Group LLC | 2020-03-26 | — | — | US | claimed |
| EP-3464446-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2019-04-10 | — | — | EP | claimed |
| US-10100235-B2 | Two-part cyanoacrylate curable adhesive system | Henkel IP & Holding GmbH (DE) | 2018-10-16 | — | — | US | claimed |
| EP-3004120-B1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | UNIV NANYANG TECH (SG) | 2018-08-29 | — | — | EP | claimed |
| WO-2017202698-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2017-11-30 | — | — | WO | claimed |
| US-20170335151-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | HENKEL AG & CO. KGAA (DE) | 2017-11-23 | — | — | US | claimed |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-19 | — | — | US | claimed |
| EP-3004120-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | Nanyang Technological University (SG) | 2016-04-13 | — | — | EP | claimed |
| WO-2014196930-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-12-11 | — | — | WO | claimed |
| EP-2346956-A1 | ACTIVATORS FOR TWO PART CYANOACRYLATE ADHESIVES | Loctite (R & D) Limited (IE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010046412-A1 | ACTIVATORS FOR TWO PART CYANOACRYLATE ADHESIVES | LOCTITE (R & D) LIMITED (IE) | 2010-04-29 | — | — | WO | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4732907-A1 | STYRYL BENZOTHIAZOLIUM SALTS AND ITS USES AGAINST PARASITIC INFECTIONS | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2026-04-29 | — | — | EP | disclosed |
| EP-4733299-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Braegen Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4653435-A1 | PRMT5-MTA INHIBITOR | Suzhou Puhe Biopharma Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119522221-A | Cyanine dye, preparation method and application thereof, sample analysis method and analyzer | 深圳迈瑞生物医疗电子股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12195455-B2 | Succinate and fumarate acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-01-14 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| WO-2024240186-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳博芮健制药有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-118561835-B | TADF guiding modification endoplasmic reticulum targeting photosensitizer and application thereof in tumor immunotherapy | 山东第二医科大学 | 2024-10-18 | — | — | CN | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024199341-A1 | FUSED POLYCYCLIC DERIVATIVE AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240318052-A1 | METHOD OF UNDERWATER BONDING | HENKEL AG & CO KGAA (DE) | 2024-09-26 | — | — | US | disclosed |
| US-20240309038-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-09-19 | — | — | US | disclosed |
| CN-118561835-A | TADF guiding modification endoplasmic reticulum targeting photosensitizer and application thereof in tumor immunotherapy | 山东第二医科大学 | 2024-08-30 | — | — | CN | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024152973-A1 | PRMT5-MTA INHIBITOR | 苏州浦合医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118359607-A | PRMT5-MTA inhibitors | 苏州浦合医药科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118359640-A | PRMT5-MTA inhibitors | 苏州浦合医药科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118355041-A | Method for underwater bonding | 汉高股份有限及两合公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-118139862-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024067694-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024039861-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-11897880-B2 | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117466834-A | Cyanine dye, its preparation method and use | 深圳迈瑞生物医疗电子股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024017247-A1 | CYANINE DYE AND PREPARATION METHOD THEREFOR AND USE THEREOF, SAMPLE ANALYSIS METHOD, AND ANALYZER | 深圳迈瑞生物医疗电子股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-11835457-B2 | Fluorescent composition for detecting biological material | BIOACTS CORPORATION (KR) | 2023-12-05 | — | — | US | disclosed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4267568-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-110128843-B | Fluorescent dye and preparation method and application thereof | 深圳大学 | 2023-07-14 | — | — | CN | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| EP-3841093-B1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023099777-A1 | METHOD OF UNDERWATER BONDING | Henkel IP & Holding GmbH (DE) | 2023-06-08 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220389005-A1 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220228985-A1 | FLUORESCENT COMPOSITION FOR DETECTING BIOLOGICAL MATERIAL | BIOACTS CORPORATION | 2022-07-21 | — | — | US | disclosed |
| WO-2022144274-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-07-07 | — | — | WO | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| EP-3744810-B1 | FLUORESCENT DYE, PREPARATION METHOD THEREFOR AND USE THEREOF | UNIV SHENZHEN (CN) | 2022-06-01 | — | — | EP | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| CN-110003271-B | Process for producing aromatic compound | 住友化学株式会社 | 2022-05-03 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2022-03-01 | — | — | US | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-111116573-B | Near-infrared fluorescent probe for simultaneously detecting DNA and RNA under dual channels and preparation method and application thereof | 中山大学 | 2021-08-06 | — | — | CN | disclosed |
| US-20210198250-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-07-01 | — | — | US | disclosed |
| EP-3841093-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-11045796-B2 | Process for producing aromatic compound, and palladium complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| CN-113045563-A | Preparation method of blue light spectrum sensitizing agent | 上海泓博智源医药股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-113045563-A | Preparation method of blue light spectrum sensitizing agent | 上海泓博智源医药股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3464446-B1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2021-06-23 | — | — | EP | disclosed |
| CN-111217806-B | Hemicyanine compound based on benzothiazole-linked heterocycle and preparation method and application thereof | 中国科学院化学研究所 | 2021-06-01 | — | — | CN | disclosed |
| EP-3822253-A1 | METHOD FOR PREPARING PROPANEDINITRILE OXIME ETHER COMPOUND AND INTERMEDIATE COMPOUND | Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| CN-109476874-B | Two-part cyanoacrylate curable adhesive systems | 汉高知识产权控股有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| CN-108368142-B | Method for producing aromatic compound and palladium complex | 住友化学株式会社 | 2021-02-19 | — | — | CN | disclosed |
| US-10889901-B2 | Ultraviolet-stabilized corrosion inhibitors | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889719-B2 | Fluorescent dye, preparation method therefor and use thereof | SHENZHEN UNIVERSITY (CN) | 2021-01-12 | — | — | US | disclosed |
| EP-3744810-A1 | FLUORESCENT DYE, PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen University (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3672959-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| CN-111217806-A | Hemicyanine compound based on benzothiazole-linked heterocycle and preparation method and application thereof | 中国科学院化学研究所 | 2020-06-02 | — | — | CN | disclosed |
| US-10655015-B2 | Tire crumb-based bitumen polymer for producing a lower viscosity asphalt with improved tolerance to high temperatures | Argopro Group LLC (US) | 2020-05-19 | — | — | US | disclosed |
| CN-111116573-A | Near-infrared fluorescent probe for simultaneously detecting DNA and RNA under dual channels and preparation method and application thereof | 中山大学 | 2020-05-08 | — | — | CN | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20200095425-A1 | FLUORESCENT DYE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| US-20200095424-A1 | TIRE CRUMB-BASED BITUMEN POLYMER FOR PRODUCING A LOWER VISCOSITY ASPHALT WITH IMPROVED TOLERANCE TO HIGH TEMPERATURES | Argopro Group LLC | 2020-03-26 | — | — | US | disclosed |
| WO-2020039030-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| US-20200032401-A1 | ULTRAVIOLET-STABILIZED CORROSION INHIBITORS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-01-30 | — | — | US | disclosed |
| EP-3085698-B1 | PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION | UNIV KYOTO (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10463391-B2 | Magnetic ferrocenyl-functionalized nanoparticle | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-11-05 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| CN-110128843-A | Fluorescent dye and its preparation method and application | 深圳大学 | 2019-08-16 | — | — | CN | disclosed |
| US-10370397-B2 | Phosphine substituted ferrocenyl complex | Kind Fahd University of Petroleum and Minerals (SA) | 2019-08-06 | — | — | US | disclosed |
| CN-110003271-A | The preparation method of aromatic compound | 住友化学株式会社 | 2019-07-12 | — | — | CN | disclosed |
| CN-105829291-B | Pain-associated compounds and pharmaceutical compositions | 国立大学法人京都大学 | 2019-05-21 | — | — | CN | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| EP-3464446-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-3455218-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| US-20190031697-A1 | PHOSPHINE SUBSTITUTED FERROCENYL COMPLEX | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-01-31 | — | — | US | disclosed |
| US-20190029718-A1 | MAGNETIC FERROCENYL-FUNCTIONALIZED NANOPARTICLE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-01-31 | — | — | US | disclosed |
| US-20190036039-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3432381-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2019-01-23 | — | — | EP | disclosed |
| EP-3432381-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2019-01-23 | — | — | EP | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180369799-A1 | PROCESS FOR PRODUCING AROMATIC COMPOUND, AND PALLADIUM COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-12-27 | — | — | US | disclosed |
| US-10150110-B2 | Method for making and using a solid-supported catalyst | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-11 | — | — | US | disclosed |
| US-10150111-B2 | Method for catalytic synthesis of cinnamic acid with catalyst recycle | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-11 | — | — | US | disclosed |
| US-10150109-B2 | Palladium(II)-silica supported catalyst | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-11 | — | — | US | disclosed |
| US-20180326410-A1 | METHOD FOR CATALYTIC SYNTHESIS OF CINNAMIC ACID WITH CATALYST RECYCLE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-15 | — | — | US | disclosed |
| US-20180326409-A1 | METHOD FOR MAKING AND USING A SOLID-SUPPORTED CATALYST | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-15 | — | — | US | disclosed |
| US-10125159-B2 | Functionalized magnetic nanoparticle, a catalyst, a method for forming C—C bonds | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-13 | — | — | US | disclosed |
| US-10100235-B2 | Two-part cyanoacrylate curable adhesive system | Henkel IP & Holding GmbH (DE) | 2018-10-16 | — | — | US | disclosed |
| EP-3385270-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND, AND PALLADIUM COMPLEX | Sumitomo Chemical Company, Ltd (JP) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018153508-A2 | SULFOXIMINE GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2018-08-30 | — | — | WO | disclosed |
| EP-3004120-B1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | UNIV NANYANG TECH (SG) | 2018-08-29 | — | — | EP | disclosed |
| US-10058856-B2 | Method for palladium-catalyzed cinammic acid formation | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-08-28 | — | — | US | disclosed |
| CN-108368142-A | Method for producing aromatic compound and palladium complex | 住友化学株式会社 | 2018-08-03 | — | — | CN | disclosed |
| US-20180200706-A1 | PALLADIUM(II)-SILICA SUPPORTED CATALYST | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-07-19 | — | — | US | disclosed |
| US-20180200705-A1 | METHOD FOR PALLADIUM-CATALYZED CINAMMIC ACID FORMATION | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-07-19 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-9982087-B2 | Method for producing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-9956550-B2 | Solid-supported palladium(II) complex for catalyzing Mizoroki-Heck coupling reactions and a method thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-05-01 | — | — | US | disclosed |
| US-20180099987-A1 | FUNCTIONALIZED MAGNETIC NANOPARTICLE, A CATALYST, A METHOD FOR FORMING C-C BONDS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-04-12 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180065117-A1 | SOLID-SUPPORTED PALLADIUM(II) COMPLEX FOR CATALYZING MIZOROKI-HECK COUPLING REACTIONS AND A METHOD THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-03-08 | — | — | US | disclosed |
| EP-2871199-B1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-02-21 | — | — | EP | disclosed |
| EP-3277670-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277672-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277671-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017202698-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | Henkel IP & Holding GmbH (DE) | 2017-11-30 | — | — | WO | disclosed |
| US-20170335151-A1 | TWO-PART CYANOACRYLATE CURABLE ADHESIVE SYSTEM | HENKEL AG & CO. KGAA (DE) | 2017-11-23 | — | — | US | disclosed |
| WO-2017197046-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| EP-3229801-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-9745275-B2 | Pain-related compound and medical composition | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745275-B2 | Pain-related compound and medical composition | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745275-B2 | Pain-related compound and medical composition | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| EP-2871198-B1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-20170029389-A1 | PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION | KYOTO UNIVERSITY (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029389-A1 | PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION | KYOTO UNIVERSITY (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029389-A1 | PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION | KYOTO UNIVERSITY (JP) | 2017-02-02 | — | — | US | disclosed |
| CN-103951631-B | A kind of synthetic method of benzoxazole derivative | 重庆大学 | 2017-01-04 | — | — | CN | disclosed |
| CN-103880827-B | The application of the reuptake of aryl and the substituted tetrahydroisoquinoline of heteroaryl and blocking-up norepinephrine, dopamine and serotonin | 阿尔巴尼分子研究公司 | 2017-01-04 | — | — | CN | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-9499531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| EP-3085698-A1 | PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION | Kyoto University (JP) | 2016-10-26 | — | — | EP | disclosed |
| EP-3085698-A1 | PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION | Kyoto University (JP) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016161279-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161286-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161269-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
| US-9453103-B2 | Method for producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9428528-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428528-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428528-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-08-30 | — | — | US | disclosed |
| CN-104540871-B | The preparation method of aromatic compound | 住友化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| EP-2166060-B1 | Stabilized aqueous polymer compositions | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| CN-105829291-A | Pain-associated compounds and pharmaceutical compositions | 国立大学法人京都大学 | 2016-08-03 | — | — | CN | disclosed |
| US-20160200861-A1 | METHOD FOR PRODUCING COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20160194342-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194342-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194342-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2016-07-07 | — | — | US | disclosed |
| EP-3037398-A1 | METHOD FOR MANUFACTURING CHEMICAL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016094260-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094260-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-19 | — | — | US | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9340564-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340564-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340564-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-05-17 | — | — | US | disclosed |
| EP-3004120-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | Nanyang Technological University (SG) | 2016-04-13 | — | — | EP | disclosed |
| US-9238665-B2 | Method for producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150322199-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322101-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2287141-B1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150274713-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | CURIA GLOBAL, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150266910-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266910-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266910-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2015-09-24 | — | — | US | disclosed |
| EP-1778639-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9120794-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-9108948-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9085531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-9073894-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073894-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073894-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| CN-104684959-A | Process for producing aromatic compound | SUMITOMO CHEMICAL CO | 2015-06-03 | — | — | CN | disclosed |
| EP-2871199-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2015-05-13 | — | — | EP | disclosed |
| EP-2871198-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2015-05-13 | — | — | EP | disclosed |
| CN-104540871-A | Method for producing aromatic compound | SUMITOMO CHEMICAL CO | 2015-04-22 | — | — | CN | disclosed |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-8962715-B2 | Stabilized aqueous polymer compositions and their use | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8957219-B2 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | SHIONOGI & CO., LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957219-B2 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | SHIONOGI & CO., LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957219-B2 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | SHIONOGI & CO., LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8952180-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | disclosed |
| EP-2822934-A1 | PHENICOL ANTIBACTERIALS | Zoetis LLC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8933168-B2 | Activators for two part cyanoacrylate adhesives | Henkel IP & Holding GmbH (DE) | 2015-01-13 | — | — | US | disclosed |
| US-8933168-B2 | Activators for two part cyanoacrylate adhesives | Henkel IP & Holding GmbH (DE) | 2015-01-13 | — | — | US | disclosed |
| EP-2351744-B1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | SHIONOGI & CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2351744-B1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | SHIONOGI & CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014196930-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-12-11 | — | — | WO | disclosed |
| US-8883779-B2 | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them | SHINOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8829041-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2760829-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2757105-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbvie Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2014109712-A1 | PALLADIUM-CATALYZED ASYMMETRIC (HETERO)ARYLATION AND VINYLATION OF KETONE ENOLATES TO PRODUCE TERTIARY STEREOCENTERS AT ALPHA(α)-POSITION | NANAYNG TECHNOLOGICAL UNIVERSITY (SG) | 2014-07-17 | — | — | WO | disclosed |
| CN-103880827-A | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RES INC | 2014-06-25 | — | — | CN | disclosed |
| US-8741901-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2703399-A1 | OXAZINE DERIVATIVE AND BACE 1 INHIBITOR CONTAINING SAME | Shionogi & Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140051691-A1 | OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM | SHIONOGI & CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-103382174-A | Cyclopropyl amine derivatives as histamin h3 receptor modulators | ABBOTT LAB | 2013-11-06 | — | — | CN | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2013134061-A1 | PHENICOL ANTIBACTERIALS | ZOETIS LLC (US) | 2013-09-12 | — | — | WO | disclosed |
| CN-102015585-B | Method for producing unsaturated organic compound | SUMITOMO CHEMICAL CO | 2013-06-19 | — | — | CN | disclosed |
| CN-102008459-B | Antibacterial agents | BIOTA SCIENT MAN | 2013-05-29 | — | — | CN | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130005965-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-03 | — | — | US | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-8237002-B2 | Method for producing unsaturated organic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236796-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8227486-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| CN-102459249-A | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases | EXELIXIS INC | 2012-05-16 | — | — | CN | disclosed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1888523-B1 | CYCLOBUTYL AMINE DERIVATIVES | ABBOTT LAB (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| CN-101404989-B | Antibacterial agent | PROLYSIS LTD | 2011-10-05 | — | — | CN | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110196092-A1 | ACTIVATORS FOR TWO PART CYANOACRYLATE ADHESIVES | LOCTITE (R&D) LIMITED (IE) | 2011-08-11 | — | — | US | disclosed |
| US-20110196092-A1 | ACTIVATORS FOR TWO PART CYANOACRYLATE ADHESIVES | LOCTITE (R&D) LIMITED (IE) | 2011-08-11 | — | — | US | disclosed |
| EP-2351744-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | Shionogi & Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351744-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | Shionogi & Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2311831-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311831-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | disclosed |
| CN-102015585-A | Method for producing unsaturated organic compound | SUMITOMO CHEMICAL CO | 2011-04-13 | — | — | CN | disclosed |
| CN-102008459-A | Antibacterial agents | PROLYSIS LTD | 2011-04-13 | — | — | CN | disclosed |
| EP-2298734-A2 | Cyclobutyl amine derivatives | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1620434-B1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-1620434-B1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046380-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2287141-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| CN-101952267-A | Cyclopropylamine Derivatives | ABBOTT LAB | 2011-01-19 | — | — | CN | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7807697-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807697-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807697-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2231631-A1 | CYCLOPROPYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| CN-101072762-B | Phenyl-piperazin methanone derivatives | HOFFMANN LA ROCHE | 2010-06-23 | — | — | CN | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2010057833-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010046412-A1 | ACTIVATORS FOR TWO PART CYANOACRYLATE ADHESIVES | LOCTITE (R & D) LIMITED (IE) | 2010-04-29 | — | — | WO | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100075871-A1 | Stabilized aqueous polymer compositions and their use | TOUGAS HOLDING GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| EP-2166060-A1 | Stabilized aqueous polymer compositions and their use | Allessa Chemie GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| US-7683218-B2 | Method for producing thioether compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7683218-B2 | Method for producing thioether compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| WO-2010011964-A2 | IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010001220-A1 | NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS SA (FR) | 2010-01-07 | — | — | WO | disclosed |
| EP-2141164-A1 | New 1,2,4-triazine derivatives and biological applications thereof | Mutabilis (FR) | 2010-01-06 | — | — | EP | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7629340-B2 | N-(6-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090253906-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227593-A1 | CYCLOBUTYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2097405-A2 | ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7576198-B1 | Integrase inhibitors containing aromatic heterocycle derivatives | SHIONOGI & CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576198-B1 | Integrase inhibitors containing aromatic heterocycle derivatives | SHIONOGI & CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085226-A2 | INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| CN-101472887-A | Cyclopropylamine derivatives as modulators of the histamine H3 receptor | ABBOTT LAB (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7553964-B2 | Cyclobutyl amine derivatives | ABBOTT LABORATORIES (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009079225-A1 | CYCLOPROPYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-7541357-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | AMR TECHNOLOGY, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1828154-B1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-2049472-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | Abbott Laboratories (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-101404989-A | Antibacterial agent | PROLYSIS LTD (GB) | 2009-04-08 | — | — | CN | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| CN-101379559-A | Metal chelate compounds and their use in optical recording media with high storage capacity | CIBA SC HOLDING AG (CH) | 2009-03-04 | — | — | CN | disclosed |
| US-20090048443-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1976829-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080242653-A1 | Cyclopropyl amine derivatives | ABBVIE INC. | 2008-10-02 | — | — | US | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080193700-A1 | Metal Chelates and Their Use in Optical Recording Media Having High Storage Capacity | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080119520-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119520-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119520-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | US | disclosed |
| CN-100387576-C | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2008-05-14 | — | — | CN | disclosed |
| US-20080108823-A1 | Method For Producing Thioether Compound | MSD K.K. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108823-A1 | Method For Producing Thioether Compound | MSD K.K. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| CN-101137414-A | Multicyclic bis-amide mmp inhibitors | ALANTOS PHARMACEUTICALS INC (US) | 2008-03-05 | — | — | CN | disclosed |
| EP-1888523-A2 | CYCLOBUTYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2008-02-20 | — | — | EP | disclosed |
| CN-101119969-A | Aryl and heteroaryl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine, and serotonin | AMR TECHNOLOGY INC (US) | 2008-02-06 | — | — | CN | disclosed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007150010-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| CN-101072762-A | Phenyl-piperazin methanone derivatives | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | CN | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| EP-1843820-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1828154-A1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| CN-101031539-A | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORP (JP) | 2007-09-05 | — | — | CN | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1806337-A1 | METHOD FOR PRODUCING THIOETHER COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7241761-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007070556-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070078133-A1 | Cyclobutyl amine derivatives | ABBVIE INC. | 2007-04-05 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006132914-A2 | CYCLOBUTYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| US-7094790-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-08-22 | — | — | US | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | US | disclosed |
| WO-2006061135-A1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| WO-2006048727-A1 | PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060063766-A1 | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | disclosed |
| CN-1742007-A | Indole-derivative modulators of steroid hormone nuclear receptors | LILLY CO ELI (US) | 2006-03-01 | — | — | CN | disclosed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1620434-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| CN-1653032-A | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2005-08-10 | — | — | CN | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004101559-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | disclosed |
| CN-1097052-C | Process for prodn. of amidinoindole derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 2002-12-25 | — | — | CN | disclosed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002032891-A1 | FLAVAN COMPOUNDS, THEIR PREPARATION AND THEIR USE IN THERAPY | RIBOTARGETS LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | disclosed |
| CN-1062865-C | Process for production of amidinobenzofuran and amidionbenzothiophen derivatives and salt thereof | DAIICHI SEIYAKU CO (JP) | 2001-03-07 | — | — | CN | disclosed |
| EP-0652472-B1 | Silver halide photographic material | FUJI PHOTO FILM CO LTD (JP) | 2000-05-17 | — | — | EP | disclosed |
| CN-1049434-C | Aromatic amidine derivatives and pharmaceutically acceptable salts thereof | DAIICHI SEIYAKU CO (JP) | 2000-02-16 | — | — | CN | disclosed |
| US-5962695-A | ANTICOAGULANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| CN-1168886-A | Process for production of amidinobenzofuran and amidionbenzothiophen derivatives and salt thereof | DAIICHI SEIYAKU CO (JP) | 1997-12-31 | — | — | CN | disclosed |
| CN-1168885-A | Process for prodn. of amidinoindole derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1997-12-31 | — | — | CN | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| US-5449600-A | Bromo-substituted monomethine thiacyanine dye | FUJI PHOTO FILM CO., LTD. (JP) | 1995-09-12 | — | — | US | disclosed |
| EP-0652472-A1 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1995-05-10 | — | — | EP | disclosed |
| CN-1072677-A | Aromatic amidine derivative and salt thereof | DAIICHI SEIYAKU CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| CN-1009831-B | PROCESS FOR PREPARING HETEROCYCLE-OXO-2,3-DIAZANAPHTHYL-ACETIC ACID | PFIZER (US) | 1990-10-03 | — | — | CN | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| CN-86108308-A | Heterocycle oxo-2 guanidine-acetic acid | — | 1987-07-15 | — | — | CN | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150109-B2 | Palladium(II)-silica supported catalyst | PDK2, SIK2, SIK1 | SMN1; SMN2 1908/4885ALDH1A1 1484/4885NPC1 1383/4885 |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | SMN1; SMN2 4308/4885ALDH1A1 1037/4885NPC1 983/4885 |
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SMN1; SMN2 3774/4885ALDH1A1 347/4885NPC1 2281/4885 |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | SMN1; SMN2 722/4885ALDH1A1 862/4885NPC1 2614/4885 |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | SMN1; SMN2 1440/4885ALDH1A1 2651/4885NPC1 2540/4885 |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | SMN1; SMN2 103/4885ALDH1A1 1429/4885NPC1 512/4885 |
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | SMN1; SMN2 1002/4885ALDH1A1 947/4885NPC1 471/4885 |
| US-20060063766-A1 | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin | SLC6A3, SLC6A4, SLC6A2 | SMN1; SMN2 3707/4885ALDH1A1 984/4885NPC1 1332/4885 |
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | SMN1; SMN2 4280/4885ALDH1A1 707/4885NPC1 2825/4885 |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | SMN1; SMN2 3705/4885ALDH1A1 3395/4885NPC1 1583/4885 |
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | SMN1; SMN2 1858/4885ALDH1A1 2837/4885NPC1 978/4885 |
| US-11897880-B2 | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors | F2, F13B, SERPINE1 | SMN1; SMN2 4540/4885ALDH1A1 2124/4885NPC1 3733/4885 |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | HRH4, HRH3, HNMT | SMN1; SMN2 2666/4885ALDH1A1 852/4885NPC1 469/4885 |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | MRPL21, TTL, CTSL | SMN1; SMN2 4308/4885ALDH1A1 3505/4885NPC1 2405/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SMN1; SMN2 3245/4885ALDH1A1 3454/4885NPC1 2220/4885 |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | SMN1; SMN2 1424/4885ALDH1A1 2649/4885NPC1 1253/4885 |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | SMN1; SMN2 69/4885ALDH1A1 1389/4885NPC1 719/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SMN1; SMN2 4153/4885ALDH1A1 2819/4885NPC1 3838/4885 |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | SMN1; SMN2 867/4885ALDH1A1 1200/4885NPC1 2106/4885 |
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | SMN1; SMN2 441/4885ALDH1A1 1766/4885NPC1 981/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | SMN1; SMN2 2545/4885ALDH1A1 1346/4885NPC1 337/4885 |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | SMN1; SMN2 3366/4885ALDH1A1 787/4885NPC1 2815/4885 |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | SMN1; SMN2 3119/4885ALDH1A1 219/4885NPC1 776/4885 |
| US-20180099987-A1 | FUNCTIONALIZED MAGNETIC NANOPARTICLE, A CATALYST, A METHOD FOR FORMING C-C BONDS | MSN, COIL, NSFL1C | SMN1; SMN2 804/4885ALDH1A1 3106/4885NPC1 1010/4885 |
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885ALDH1A1 128/4885NPC1 39/4885 |
| US-20180326409-A1 | METHOD FOR MAKING AND USING A SOLID-SUPPORTED CATALYST | AOC1, SOD1, PDK2 | SMN1; SMN2 2205/4885ALDH1A1 891/4885NPC1 1471/4885 |
| US-11045796-B2 | Process for producing aromatic compound, and palladium complex | DDT, DRD1, DRD2 | SMN1; SMN2 4456/4885ALDH1A1 1822/4885NPC1 2704/4885 |
| US-10889901-B2 | Ultraviolet-stabilized corrosion inhibitors | TYR, UNG, MGMT | SMN1; SMN2 3108/4885ALDH1A1 109/4885NPC1 4864/4885 |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | SMN1; SMN2 4657/4885ALDH1A1 3915/4885NPC1 2514/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | SMN1; SMN2 1656/4885ALDH1A1 2460/4885NPC1 2435/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | SMN1; SMN2 1440/4885ALDH1A1 2651/4885NPC1 2540/4885 |
| US-20200032401-A1 | ULTRAVIOLET-STABILIZED CORROSION INHIBITORS | TYR, UNG, MGMT | SMN1; SMN2 3108/4885ALDH1A1 109/4885NPC1 4864/4885 |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SMN1; SMN2 4811/4885ALDH1A1 388/4885NPC1 1165/4885 |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | SBK1, SIK1, PDPK1 | SMN1; SMN2 4202/4885ALDH1A1 576/4885NPC1 3757/4885 |
| US-12195455-B2 | Succinate and fumarate acid addition salts of piperazine derivatives | FH, SDHA, SDHB | SMN1; SMN2 3693/4885ALDH1A1 185/4885NPC1 2257/4885 |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | SMN1; SMN2 722/4885ALDH1A1 862/4885NPC1 2614/4885 |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | SMN1; SMN2 3638/4885ALDH1A1 2091/4885NPC1 645/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | SMN1; SMN2 1208/4885ALDH1A1 800/4885NPC1 1400/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | SMN1; SMN2 4280/4885ALDH1A1 707/4885NPC1 2825/4885 |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | GRIK5, GRM5, GRIN2C | SMN1; SMN2 935/4885ALDH1A1 246/4885NPC1 990/4885 |
| US-20180326410-A1 | METHOD FOR CATALYTIC SYNTHESIS OF CINNAMIC ACID WITH CATALYST RECYCLE | DDT, PDK2, CLK2 | SMN1; SMN2 2995/4885ALDH1A1 648/4885NPC1 1008/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | SMN1; SMN2 669/4885ALDH1A1 955/4885NPC1 2286/4885 |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | LIPG, CEL, LIPA | SMN1; SMN2 4521/4885ALDH1A1 1177/4885NPC1 2304/4885 |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | SMN1; SMN2 3671/4885ALDH1A1 796/4885NPC1 1197/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | SMN1; SMN2 831/4885ALDH1A1 1033/4885NPC1 2125/4885 |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, PNLIP | SMN1; SMN2 4858/4885ALDH1A1 417/4885NPC1 1580/4885 |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | IL1B, IL1A, NFKBIA | SMN1; SMN2 3343/4885ALDH1A1 205/4885NPC1 2436/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | SMN1; SMN2 4594/4885ALDH1A1 1806/4885NPC1 2374/4885 |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | SMN1; SMN2 2528/4885ALDH1A1 777/4885NPC1 1096/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | SMN1; SMN2 2959/4885ALDH1A1 740/4885NPC1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.